92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts

CCR9 is as an interesting target for the treatment of human CCR9+-T cell acute lymphoblastic leukemia, since its expression is limited to immature cells in the thymus, infiltrating leukocytes in the small intestine and a small fraction of mature circulating T lymphocytes. 92R, a new mouse mAb (IgG2a...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Beatriz Somovilla-Crespo, Maria Teresa Martín Monzón, Maria Vela, Isabel Corraliza-Gorjón, Silvia Santamaria, Jose A. Garcia-Sanz, Leonor Kremer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-01-01
Subjects:	cancer therapeutic antibodies combinations oncology chemokine receptors
Online Access:	http://journal.frontiersin.org/article/10.3389/fimmu.2018.00077/full